Načítá se...
Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies
BACKGROUND: Pre-exposure prophylaxis (PrEP) using antiretroviral (ARV) agents has been shown to effectively prevent human immunodeficiency virus type 1 (HIV-1) acquisition in high-risk populations. However, the efficacy of these regimens is highly variable, which is thought to be largely due to the...
Uloženo v:
| Vydáno v: | J Acquir Immune Defic Syndr |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5123706/ https://ncbi.nlm.nih.gov/pubmed/27792681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000001119 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|